Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Vaccinations

Vaccinations

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis.

Leukemia & lymphoma·2023

Same author

Carbohydrate antigens as possible parasite vaccines A case for the Leishmania glycolipid.

Immunology today·2014

Same author

Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity.

Parasitology·2009

Same author

Wound healing response is a major contributor to the severity of cutaneous leishmaniasis in the ear model of infection.

Parasite immunology·2007

Same author

What can bioinformatics do for parasitology research?

Parasitology today (Personal ed.)·2006

Same author

A simple method allowing DIC imaging in conjunction with confocal microscopy.

Journal of microscopy·2005

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

Leishmania vaccines: progress and problems.

L Kedzierski¹, Y Zhu, E Handman

¹Infection and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3050, Melbourne, Australia. kedzierski@wehi.edu.au

|February 6, 2007

Summary

Developing a vaccine for leishmaniasis, a parasitic disease spread by sandflies, faces challenges in translating animal model success to human application. Research advances offer new avenues, but field implementation remains a hurdle.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Related Experiment Videos

Last Updated: Jul 17, 2026

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Area of Science:

* Parasitology and Tropical Medicine
* Vaccine Development and Immunology

Background:

* Leishmaniasis is a significant global health issue caused by Leishmania parasites transmitted by sandflies, affecting millions annually.
* Current chemotherapy treatments for leishmaniasis are costly, difficult to administer, and increasingly ineffective due to drug resistance.
* The feasibility of a leishmaniasis vaccine is supported by the parasite's life cycle and natural host immunity post-infection.

Purpose of the Study:

* To review recent advancements in the development of anti-leishmania vaccines.
* To examine the obstacles hindering the development and implementation of these vaccines.
* To explore new research directions informed by Leishmania pathogenesis, host immunity, and genomic data.

Main Methods:

* Comprehensive literature review of recent studies on anti-leishmania vaccine development.
* Analysis of data from animal models demonstrating vaccine efficacy.
* Examination of challenges in translating preclinical findings to human clinical trials and field application.

Main Results:

* Animal models show promising protection against Leishmania infection using protein and DNA vaccines.
* Despite extensive research, no effective leishmaniasis vaccine is currently available for human use.
* Advances in understanding Leishmania pathogenesis and host immunity, alongside the genome sequence, provide new opportunities for vaccine design.

Conclusions:

* Vaccination is a highly promising strategy for controlling leishmaniasis, given the limitations of current treatments.
* Key challenges remain in bridging the gap between animal model efficacy and human disease translation, as well as in practical field implementation.
* Continued research integrating new scientific insights is crucial for overcoming hurdles in anti-leishmania vaccine development and deployment.